Browsing ICR Divisions by author "Sharp, Adam"
Now showing items 1-20 of 42
-
A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer.
Kolinsky, MP; Rescigno, P; Bianchini, D; Zafeiriou, Z; Mehra, N; et al. (ELSEVIER, 2020-02-21)BACKGROUND: Activation of the PI3K/AKT/mTOR pathway through loss of phosphatase and tensin homolog (PTEN) occurs in approximately 50% of patients with metastatic castration-resistant prostate cancer (mCRPC). Recent evidence ... -
Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer.
Li, S; Fong, K-W; Gritsina, G; Zhang, A; Zhao, JC; et al. (AMER ASSOC CANCER RESEARCH, 2019-05-15)Castration-resistant prostate cancer (CRPC) that has developed resistance to the new-generation androgen receptor (AR) antagonist enzalutamide is a lethal disease. Transcriptome analysis of multiple prostate cancer models ... -
Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors.
Neeb, A; Herranz, N; Arce-Gallego, S; Miranda, S; Buroni, L; et al. (ELSEVIER, 2020-11-08)BACKGROUND: Deleterious ATM alterations are found in metastatic prostate cancer (PC); PARP inhibition has antitumour activity against this subset, but only some ATM loss PCs respond. OBJECTIVE: To characterise ATM-deficient ... -
Alternative splicing in prostate cancer.
Paschalis, A; Sharp, A; Welti, JC; Neeb, A; Raj, GV; et al. (NATURE PUBLISHING GROUP, 2018-11-01)Androgen receptor (AR) splice variants (AR-Vs) have been implicated in the development and progression of metastatic prostate cancer. AR-Vs are truncated isoforms of the AR, a subset of which lack a ligand-binding domain ... -
Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
Welti, J; Rodrigues, DN; Sharp, A; Sun, S; Lorente, D; et al. (2016-10)Background The androgen receptor splice variant-7 (AR-V7) has been implicated in the development of castration-resistant prostate cancer (CRPC) and resistance to abiraterone and enzalutamide.Objective To develop a validated ... -
Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
Welti, J; Rodrigues, DN; Sharp, A; Sun, S; Lorente, D; et al. (ELSEVIER SCIENCE BV, 2016-10-01)BACKGROUND: The androgen receptor splice variant-7 (AR-V7) has been implicated in the development of castration-resistant prostate cancer (CRPC) and resistance to abiraterone and enzalutamide. OBJECTIVE: To develop a ... -
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.
Sharp, A; Coleman, I; Yuan, W; Sprenger, C; Dolling, D; et al. (AMER SOC CLINICAL INVESTIGATION INC, 2019-01-02)BACKGROUND: Liquid biopsies have demonstrated that the constitutively active androgen receptor splice variant-7 (AR-V7) associates with reduced response and overall survival from endocrine therapies in castration-resistant ... -
Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer.
Fletcher, CE; Sulpice, E; Combe, S; Shibakawa, A; Leach, DA; et al. (SPRINGERNATURE, 2019-07-11)Androgen receptor (AR) signalling is a key prostate cancer (PC) driver, even in advanced 'castrate-resistant' disease (CRPC). To systematically identify microRNAs (miRs) modulating AR activity in lethal disease, ... -
AR-V7 biomarker testing for primary prostate cancer: The ongoing challenge of analytical validation and clinical qualification.
Sowalsky, AG; Sharp, A; Trostel, SY; de Bono, JS; Plymate, SR (Elsevier BV, 2021-01-01) -
Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer.
Sowalsky, AG; Figueiredo, I; Lis, RT; Coleman, I; Gurel, B; et al. (AMER ASSOC CANCER RESEARCH, 2022-08-15)PURPOSE: Therapies targeting the androgen receptor (AR) have improved the outcome for patients with castration-sensitive prostate cancer (CSPC). Expression of the constitutively active AR splice variant-7 (AR-V7) has shown ... -
BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer.
Li, X; Baek, G; Ramanand, SG; Sharp, A; Gao, Y; et al. (CELL PRESS, 2018-01-16)BRD4 belongs to the bromodomain and extraterminal (BET) family of chromatin reader proteins that bind acetylated histones and regulate gene expression. Pharmacological inhibition of BRD4 by BET inhibitors (BETi) has indicated ... -
CD38 in Advanced Prostate Cancers.
Guo, C; Crespo, M; Gurel, B; Dolling, D; Rekowski, J; et al. (ELSEVIER, 2021-05-13)BACKGROUND: CD38, a druggable ectoenzyme, is involved in the generation of adenosine, which is implicated in tumour immune evasion. Its expression and role in prostate tumour-infiltrating immune cells (TIICs) have not been ... -
CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo.
Alajati, A; D'Ambrosio, M; Troiani, M; Mosole, S; Pellegrini, L; et al. (AMER SOC CLINICAL INVESTIGATION INC, 2020-05-01)The mechanisms by which prostate cancer shifts from an indolent castration-sensitive phenotype to lethal castration-resistant prostate cancer (CRPC) are poorly understood. Identification of clinically relevant genetic ... -
Characterizing CDK12-Mutated Prostate Cancers.
Rescigno, P; Gurel, B; Pereira, R; Crespo, M; Rekowski, J; et al. (AMER ASSOC CANCER RESEARCH, 2020-09-28)PURPOSE: Cyclin-dependent kinase 12 (CDK12) aberrations have been reported as a biomarker of response to immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). Herein, we characterize CDK12-mutated ... -
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.
Goodall, J; Mateo, J; Yuan, W; Mossop, H; Porta, N; et al. (AMER ASSOC CANCER RESEARCH, 2017-09-01)Biomarkers for more precise patient care are needed in metastatic prostate cancer. We have reported a phase II trial (TOPARP-A) of the PARP inhibitor olaparib in metastatic prostate cancer, demonstrating antitumor activity ... -
Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.
Sharp, A; Welti, JC; Lambros, MBK; Dolling, D; Rodrigues, DN; et al. (ELSEVIER, 2019-11-01)BACKGROUND: Detection of androgen receptor splice variant-7 (AR-V7) mRNA in circulating tumour cells (CTCs) is associated with worse outcome in metastatic castration-resistant prostate cancer (mCRPC). However, studies ... -
Development and Validation of a New BAG-1L-Specific Antibody to Quantify BAG-1L Protein Expression in Advanced Prostate Cancer.
Neeb, A; Figueiredo, I; Gurel, B; Nava Rodrigues, D; Rekowski, J; et al. (ELSEVIER SCIENCE INC, 2023-08-29)BCL-2-associated athanogene-1L (BAG-1L) is a critical co-regulator that binds to and enhances the transactivation function of the androgen receptor, leading to prostate cancer development and progression. Studies investigating ... -
Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer.
Cato, L; Neeb, A; Sharp, A; Buzón, V; Ficarro, SB; et al. (ELIFE SCIENCES PUBLICATIONS LTD, 2017-08-10)Targeting the activation function-1 (AF-1) domain located in the N-terminus of the androgen receptor (AR) is an attractive therapeutic alternative to the current approaches to inhibit AR action in prostate cancer (PCa). ... -
Development of molecularly targeted agents and immunotherapies in small cell lung cancer.
Sharp, A; Bhosle, J; Abdelraouf, F; Popat, S; O'Brien, M; et al. (ELSEVIER SCI LTD, 2016-06-01)Small cell lung cancer (SCLC) is a smoking-induced malignancy with multiple toxin-associated mutations, which accounts for 15% of all lung cancers. It remains a clinical challenge with a rapid doubling time, early dissemination ... -
Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers.
Rescigno, P; Lorente, D; Dolling, D; Ferraldeschi, R; Rodrigues, DN; et al. (ELSEVIER, 2018-05-01)BACKGROUND: Loss of PTEN is a common genomic aberration in castration-resistant prostate cancer (CRPC) and is frequently concurrent with ERG rearrangements, causing resistance to next-generation hormonal treatment (NGHT) ...